FDA APPROVES TREATMENT FOR HAIRY CELL LEUKEMIA

    FDA approves new kind of treatment for hairy cell leukemia

    Sep 13, 2018 · FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia
    Continue

    FDA approves new treatment for people with hairy cell leukemia

    1 day ago · AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved LUMOXITI ™ (moxetumomab pasudotox-tdfk
    Continue

    FDA Approves New Treatment for Hairy Cell Leukemia

    The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
    Continue

    FDA Approves AstraZeneca’s Treatment for Hairy Cell Leukemia

    The FDA approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
    Continue

    FDA approves new kind of treatment for hairy cell leukemia

    1 day ago · SILVER SPRING, Md., Sept. 13, 2018 /PRNewswire/ — The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of
    Continue

    FDA Approves Novel Treatment for Hairy Cell Leukemia

    Sep 15, 2018 · FRIDAY, Sept. 14, 2018 — Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday. Lumoxiti, a CD22-directed cytotoxin, was approved for adults who have had at least two prior therapies for the disease.
    Continue

    FDA approves new kind of treatment for hairy cell leukemia

    1 day ago · "Lumoxiti fills an unmet need for patients with hairy cell leukemia whose disease has progressed after trying other FDA-approved therapies," said Richard Pazdur, M.D., director of the FDA…
    Continue

    FDA approves treatment for ‘hairy cell’ leukemia – UPI.com

    13 hours ago · The FDA has approved a treatment for some case of "hairy cell" leukemia, the agency announced on Thursday. Photo by EmilianDanaila/Pixabay
    Continue

    FDA Approves Novel Treatment for Hairy Cell Leukemia

    13 hours ago · FRIDAY, Sept. 14, 2018 — Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday. Lumoxiti, a CD22-directed cytotoxin, was approved …
    Continue

    FDA Approves New Treatment for Hairy Cell Leukemia

    Adults with relapsed or refractory hairy cell leukemia (HCL) now have a new treatment option. The US Food and Drug Administration just approved moxetumomab pasudotox-tdfk (Lumoxiti, AstraZeneca
    Continue

    Incoming search terms:

    Category: Uncategorized